PDGFR (imatinib-class)

Class

Tyrosine kinase inhibitor (repurposed, inhaled/oral prodrug)

Platelet-derived growth factor receptors (PDGFR-alpha and PDGFR-beta) are receptor tyrosine kinases found on the surface of mesenchymal cells such as fibroblasts, pericytes, and vascular smooth muscle cells. When their natural ligands, platelet-derived growth factors, bind, the receptors pair up and activate internal signaling cascades that drive cell growth, migration, and survival. This signaling is essential for normal tissue repair and blood vessel maturation, but when it becomes chronically overactive it contributes to abnormal thickening of blood vessel walls and excessive scar-tissue formation. Inhibiting PDGFR with a small molecule that blocks its kinase activity can slow or reverse these processes, making the target relevant in pulmonary vascular remodeling disorders, fibrotic lung and skin diseases, and certain cancers driven by mutated or overexpressed PDGFR. Imatinib, originally developed against a different kinase fusion protein, also inhibits PDGFR and has been explored for these non-cancer indications. Because systemic kinase inhibition can affect tissues throughout the body, reformulating such a drug as an inhaled agent or an oral prodrug is a strategy aimed at concentrating drug exposure where it is needed while limiting effects elsewhere.